文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

新型冠状病毒肺炎相关急性肾损伤的临床特征与危险因素

[Clinical characteristics and risk factors of acute kidney injury in coronavirus disease 2019].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2020-01-01
一句话结论COVID-19患者中9.4%发生急性肾损伤,AKI组死亡率18.9%显著高于非AKI组4.2%,AKI使死亡风险增加至3.2倍(HR=3.208)。

该回顾性队列研究纳入武汉大学中南医院和武汉市第四医院2020年1月1日至2月1日的394例COVID-19患者,按KDIGO标准分为AKI组(37例,9.4%)和非AKI组(357例)。AKI组年龄、性别、吸烟史、高血压史、恶性肿瘤史、心脑血管病史分布有显著差异;AKI组白细胞计数、中性粒细胞计数、谷草转氨酶、乳酸脱氢酶、D-二聚体、降钙素原、C反应蛋白显著高于非AKI组,淋巴细胞计数和血小板计数显著降低。AKI组死亡率18.9%(7/37)显著高于非AKI组4.2%(15/357),30天累积生存率更低(log-rank P=0.003)。Cox分析显示AKI使COVID-19患者死亡风险增加至3.2倍(HR=3.208,95%CI 1.076-9.566,P=0.037)。作者认为早期干预预防AKI对改善COVID-19预后有重要意义。

要点

  • 394例COVID-19患者中37例(9.4%)发生AKI,AKI组死亡率18.9%(7/37),非AKI组4.2%(15/357),P<0.01。
  • AKI组30天累积生存率低于非AKI组(log-rank P=0.003)。
  • Cox分析显示AKI使COVID-19患者死亡风险增加至3.2倍(HR=3.208,95%CI 1.076-9.566,P=0.037)。
  • AKI组白细胞计数、中性粒细胞计数、谷草转氨酶、乳酸脱氢酶、D-二聚体、降钙素原、C反应蛋白显著高于非AKI组,淋巴细胞计数和血小板计数显著降低(均P<0.05)。
  • 两组在年龄、性别、吸烟史、高血压史、恶性肿瘤史、心血管疾病史和脑血管疾病史方面存在显著差异。

适用人群与场景

  • 2020年1月1日至2月1日在武汉大学中南医院和武汉市第四医院就诊的COVID-19患者394例,按KDIGO标准分为AKI组37例和非AKI组357例。

诊断标准与关键阈值

  • AKI诊断采用KDIGO诊断标准。

研究设计与关键结果

  • 回顾性队列研究纳入394例COVID-19患者,总死亡率5.6%,AKI发生率9.4%(37/394)。
  • AKI组死亡率18.9%(7/37)显著高于非AKI组4.2%(15/357),P<0.01。
  • AKI组30天累积生存率低于非AKI组(log-rank P=0.003)。
  • Cox分析显示AKI使COVID-19患者死亡风险增加至3.2倍(HR=3.208,95%CI 1.076-9.566,P=0.037)。
  • AKI组白细胞计数(×10⁹/L)5.75(4.13, 7.83) vs 非AKI组4.52(3.35, 5.90),P<0.05。
  • AKI组中性粒细胞计数(×10⁹/L)4.55(2.81, 6.11) vs 非AKI组3.06(2.03, 4.50),P<0.05。
  • AKI组谷草转氨酶(U/L)40.0(24.5, 69.5) vs 非AKI组30.0(23.0, 42.5),P<0.05。
  • AKI组乳酸脱氢酶(μmol×s⁻¹×L⁻¹)5.21(3.68, 7.57) vs 非AKI组4.24(3.05, 5.53),P<0.05。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,早期干预预防COVID-19患者发生AKI对改善预后有重要意义。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To investigate the characteristics and the risk factors of coronavirus disease 2019 (COVID-19) associated acute kidney injury (AKI).

METHODS: A retrospective cohort study was performed to examine the basic data, clinical characteristics and prognosis of patients with COVID-19 in Zhongnan Hospital of Wuhan University and Wuhan Fourth Hospital from January 1st to February 1st in 2020. According to the diagnostic criteria of Kidney Disease: Improving Global Outcomes (KDIGO), patients with AKI were included in AKI group and those without AKI were included in non-AKI group. The differences of each index between the two groups were compared. The prognostic value of AKI for COVID-19 was analyzed by Kaplan-Meier survival curve and Cox regression.

RESULTS: A total of 394 COVID-19 patients were included, with a total mortality of 5.6%; 37 (9.4%) of them developed AKI. The mortality of patients with COVID-19 associated AKI was 18.9%. There were significant differences in age, gender, smoking history, hypertension history, malignancy history, cardiovascular disease history and cerebrovascular disease history between the two groups. In addition to the difference of serum creatinine (SCr) and blood urea nitrogen (BUN), white blood cell count (WBC), neutrophil count (NEU), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), D-dimer, procalcitonin (PCT) and C-reaction protein (CRP) in AKI group were significantly higher than those in non-AKI group [WBC (×109/L): 5.75 (4.13, 7.83) vs. 4.52 (3.35, 5.90), NEU (×109/L): 4.55 (2.81, 6.11) vs. 3.06 (2.03, 4.50), AST (U/L): 40.0 (24.5, 69.5) vs. 30.0 (23.0, 42.5), LDH (μmol×s-1×L-1): 5.21 (3.68, 7.57) vs. 4.24 (3.05, 5.53), D-dimer (μg/L): 456 (266, 2 172) vs. 290 (152, 610), PCT (μg/L): 0.33 (0.03, 1.52) vs. 0.01 (0.01, 0.11), CRP (mg/L): 53.80 (26.00, 100.90) vs. 23.60 (9.25, 51.10), all P < 0.05], while lymphocyte count (LYM) and platelet count (PLT) were decreased [LYM (×109/L): 0.68 (0.47, 1.05) vs. 0.91 (0.63, 1.25), PLT (×109/L): 142.0 (118.0, 190.0) vs. 171.0 (130.0, 2 190.0), both P < 0.05]. The mortality of AKI group was significantly higher than that of non-AKI group [18.9% (7/37) vs. 4.2% (15/357), P < 0.01]. Kaplan-Meier survival curve showed that the 30-day cumulative survival of AKI group was lower than that of non-AKI group (log-rank: P = 0.003). Cox analysis also showed that AKI increased the odds of patients with COVID-19 mortality by 3.2-fold [hazard ratio (HR) = 3.208, 95% confidence interval (95%CI) was 1.076-9.566, P = 0.037].

CONCLUSIONS: The risk of AKI is higher in patients with COVID-19. Early intervention to prevent AKI in patients with COVID-19 is of great significance to improve the prognosis of patients.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Zhang J, Li J, Su L, et al. [Clinical characteristics and risk factors of acute kidney injury in coronavirus disease 2019]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020. PMID: 32527342. doi:10.3760/cma.j.cn121430-20200302-00198

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。